- What's Tisch?
- Stem Cell Trial
- Get Involved
ALS News Today brought consistent coverage of the latest research developments and advances in treatment related to amyotrophic lateral sclerosis (ALS) throughout 2022.
We look forward to continuing to serve as a resource for the ALS community in the new year. Here, we’ve compiled a list of the top 10 most-read stories we published this past year.
No. 1 – “Cholesterol Transporter May Be Strongest Trigger of Sporadic ALS”
Cerebrospinal fluid, or CSF, is the liquid that surrounds the brain and spinal cord. Here, researchers found that CSF taken from people with sporadic ALS, but not familial forms of the disease, induced ALS-like symptoms in mice. Further analysis revealed this effect was mainly driven by the activity of a cholesterol transport protein called ApoB100 — injecting this protein alone into mice was sufficient to cause ALS-like disease, while removing the protein prevented disease from developing. Researchers proposed that this protein may be a useful therapeutic target in ALS.
521 West 57th Street
New York, NY 10019
Support Tisch MS and our innovative research leading to treatments that improve the lives of patients.